This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tetrahydropalmatine
Accession Number
DB12093
Type
Small Molecule
Groups
Investigational
Description

Tetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity).

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Tetrahydropalmatine HydrochlorideRH72T8K75E4880-82-4MGSZZQQRTPWMEI-LMOVPXPDSA-N
Categories
UNII
3X69CO5I79
CAS number
483-14-7
Weight
Average: 355.434
Monoisotopic: 355.178358289
Chemical Formula
C21H25NO4
InChI Key
AEQDJSLRWYMAQI-KRWDZBQOSA-N
InChI
InChI=1S/C21H25NO4/c1-23-18-6-5-13-9-17-15-11-20(25-3)19(24-2)10-14(15)7-8-22(17)12-16(13)21(18)26-4/h5-6,10-11,17H,7-9,12H2,1-4H3/t17-/m0/s1
IUPAC Name
(12bS)-3,4,10,11-tetramethoxy-7,8,12b,13-tetrahydro-5H-6-azatetraphene
SMILES
COC1=CC=C2C[[email protected]@H]3N(CCC4=CC(OC)=C(OC)C=C34)CC2=C1OC

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UD(1A) dopamine receptor
antagonist
Human
UD(2) dopamine receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Tetrahydropalmatine.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Tetrahydropalmatine.Vet Approved
2,5-Dimethoxy-4-ethylamphetamineTetrahydropalmatine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineTetrahydropalmatine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineTetrahydropalmatine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineTetrahydropalmatine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tetrahydropalmatine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Tetrahydropalmatine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
AcemetacinThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tetrahydropalmatine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tetrahydropalmatine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Tetrahydropalmatine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tetrahydropalmatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tetrahydropalmatine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tetrahydropalmatine.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Tetrahydropalmatine.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Tetrahydropalmatine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tetrahydropalmatine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetrahydropalmatine.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Withdrawn
AmbrisentanTetrahydropalmatine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineTetrahydropalmatine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmisulprideTetrahydropalmatine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tetrahydropalmatine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Tetrahydropalmatine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tetrahydropalmatine.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tetrahydropalmatine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Tetrahydropalmatine.Experimental
AmphetamineTetrahydropalmatine may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetrahydropalmatine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Tetrahydropalmatine.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Tetrahydropalmatine.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Tetrahydropalmatine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tetrahydropalmatine.Approved
AtenololAtenolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Tetrahydropalmatine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Tetrahydropalmatine.Investigational, Vet Approved
AzelastineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Tetrahydropalmatine.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Tetrahydropalmatine.Experimental
BarbexacloneThe metabolism of Tetrahydropalmatine can be increased when combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Tetrahydropalmatine.Illicit
BarnidipineTetrahydropalmatine may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tetrahydropalmatine.Approved, Investigational
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
BenzphetamineTetrahydropalmatine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tetrahydropalmatine.Approved
BepridilBepridil may increase the hypotensive activities of Tetrahydropalmatine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Tetrahydropalmatine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Tetrahydropalmatine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
BosentanBosentan may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
BQ-123BQ-123 may increase the hypotensive activities of Tetrahydropalmatine.Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Tetrahydropalmatine.Experimental
BretyliumBretylium may increase the hypotensive activities of Tetrahydropalmatine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Tetrahydropalmatine.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Tetrahydropalmatine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Tetrahydropalmatine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrahydropalmatine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tetrahydropalmatine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tetrahydropalmatine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Tetrahydropalmatine.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Tetrahydropalmatine.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Tetrahydropalmatine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tetrahydropalmatine.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
BuprenorphineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetrahydropalmatine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tetrahydropalmatine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Tetrahydropalmatine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Tetrahydropalmatine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Tetrahydropalmatine.Approved
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Tetrahydropalmatine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tetrahydropalmatine.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Tetrahydropalmatine.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetrahydropalmatine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tetrahydropalmatine.Approved
CadralazineCadralazine may increase the hypotensive activities of Tetrahydropalmatine.Experimental
CafedrineTetrahydropalmatine may increase the hypotensive activities of Cafedrine.Investigational
Calcium AcetateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanTetrahydropalmatine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Tetrahydropalmatine.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Tetrahydropalmatine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Tetrahydropalmatine.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Tetrahydropalmatine.Investigational
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Tetrahydropalmatine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Tetrahydropalmatine.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tetrahydropalmatine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tetrahydropalmatine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tetrahydropalmatine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tetrahydropalmatine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
CaseinThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Tetrahydropalmatine.Approved
CeliprololCeliprolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Tetrahydropalmatine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tetrahydropalmatine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tetrahydropalmatine.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tetrahydropalmatine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tetrahydropalmatine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tetrahydropalmatine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Tetrahydropalmatine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetrahydropalmatine.Approved
ChlorphentermineTetrahydropalmatine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tetrahydropalmatine.Approved, Investigational, Withdrawn
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Tetrahydropalmatine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tetrahydropalmatine.Approved
CicletanineTetrahydropalmatine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
CilazaprilCilazapril may increase the hypotensive activities of Tetrahydropalmatine.Approved
CimetidineThe serum concentration of Tetrahydropalmatine can be increased when it is combined with Cimetidine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tetrahydropalmatine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Tetrahydropalmatine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Tetrahydropalmatine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Tetrahydropalmatine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Tetrahydropalmatine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Tetrahydropalmatine.Approved, Illicit
ClonidineClonidine may increase the hypotensive activities of Tetrahydropalmatine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tetrahydropalmatine.Approved
CloranololTetrahydropalmatine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetrahydropalmatine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clothiapine.Experimental
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Tetrahydropalmatine.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tetrahydropalmatine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tetrahydropalmatine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tetrahydropalmatine.Approved, Illicit
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Tetrahydropalmatine.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Tetrahydropalmatine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Tetrahydropalmatine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrahydropalmatine.Approved
CyclopenthiazideTetrahydropalmatine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Cyclopropane.Experimental
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tetrahydropalmatine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tetrahydropalmatine.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetrahydropalmatine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Dapoxetine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
DelaprilTetrahydropalmatine may increase the hypotensive activities of Delapril.Experimental
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Tetrahydropalmatine.Investigational
DeserpidineTetrahydropalmatine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tetrahydropalmatine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Tetrahydropalmatine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tetrahydropalmatine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Tetrahydropalmatine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrahydropalmatine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tetrahydropalmatine.Approved, Vet Approved
DextroamphetamineTetrahydropalmatine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Tetrahydropalmatine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tetrahydropalmatine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tetrahydropalmatine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tetrahydropalmatine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tetrahydropalmatine.Approved, Illicit, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Tetrahydropalmatine.Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Tetrahydropalmatine.Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Diethyl ether.Experimental
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
DiethylpropionTetrahydropalmatine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Tetrahydropalmatine.Approved, Illicit
DihydralazineDihydralazine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetrahydropalmatine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tetrahydropalmatine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tetrahydropalmatine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetrahydropalmatine.Experimental, Illicit
DiltiazemDiltiazem may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tetrahydropalmatine.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tetrahydropalmatine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetrahydropalmatine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Tetrahydropalmatine.Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Tetrahydropalmatine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Tetrahydropalmatine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Tetrahydropalmatine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tetrahydropalmatine.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tetrahydropalmatine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrahydropalmatine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tetrahydropalmatine.Experimental, Illicit
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Tetrahydropalmatine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Tetrahydropalmatine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Tetrahydropalmatine.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Tetrahydropalmatine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Eltanolone.Investigational
EnalaprilEnalapril may increase the hypotensive activities of Tetrahydropalmatine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Tetrahydropalmatine.Approved
EndralazineEndralazine may increase the hypotensive activities of Tetrahydropalmatine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Tetrahydropalmatine.Approved, Investigational
EpanololTetrahydropalmatine may increase the hypotensive activities of Epanolol.Experimental
EpoprostenolEpoprostenol may increase the hypotensive activities of Tetrahydropalmatine.Approved
EprosartanEprosartan may increase the hypotensive activities of Tetrahydropalmatine.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tetrahydropalmatine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tetrahydropalmatine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Tetrahydropalmatine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tetrahydropalmatine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tetrahydropalmatine.Approved, Investigational
EthanolTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrahydropalmatine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetrahydropalmatine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tetrahydropalmatine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrahydropalmatine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tetrahydropalmatine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tetrahydropalmatine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Tetrahydropalmatine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Tetrahydropalmatine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Tetrahydropalmatine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrahydropalmatine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tetrahydropalmatine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Tetrahydropalmatine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Tetrahydropalmatine.Approved
FelodipineFelodipine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tetrahydropalmatine.Approved, Illicit, Withdrawn
FenoldopamFenoldopam may increase the hypotensive activities of Tetrahydropalmatine.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetrahydropalmatine.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Tetrahydropalmatine.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Tetrahydropalmatine.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Tetrahydropalmatine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tetrahydropalmatine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Fluanisone.Experimental
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetrahydropalmatine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tetrahydropalmatine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tetrahydropalmatine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tetrahydropalmatine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tetrahydropalmatine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tetrahydropalmatine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetrahydropalmatine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Tetrahydropalmatine.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Tetrahydropalmatine.Experimental
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tetrahydropalmatine.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Tetrahydropalmatine.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Tetrahydropalmatine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tetrahydropalmatine.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Tetrahydropalmatine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrahydropalmatine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Tetrahydropalmatine.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tetrahydropalmatine.Approved, Illicit, Investigational
GepefrineTetrahydropalmatine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tetrahydropalmatine.Approved, Illicit
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Tetrahydropalmatine.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Tetrahydropalmatine.Approved
GuanazodineTetrahydropalmatine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Tetrahydropalmatine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
GuanoclorTetrahydropalmatine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTetrahydropalmatine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTetrahydropalmatine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Tetrahydropalmatine.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tetrahydropalmatine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tetrahydropalmatine.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Tetrahydropalmatine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tetrahydropalmatine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Tetrahydropalmatine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tetrahydropalmatine.Approved, Illicit, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Tetrahydropalmatine.Experimental
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetrahydropalmatine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Tetrahydropalmatine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Tetrahydropalmatine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved, Vet Approved
HydrocodoneTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrahydropalmatine.Approved, Illicit
HydroxyamphetamineTetrahydropalmatine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tetrahydropalmatine.Approved
IloprostIloprost may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tetrahydropalmatine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Tetrahydropalmatine.Approved
IndenololIndenolol may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Indiplon.Investigational
IndoraminIndoramin may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
Iofetamine I-123Tetrahydropalmatine may decrease the stimulatory activities of Iofetamine I-123.Approved
IproclozideIproclozide may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Tetrahydropalmatine can be increased when used in combination with Isocarboxazid.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Tetrahydropalmatine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tetrahydropalmatine.Approved, Vet Approved
IsradipineIsradipine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetrahydropalmatine.Approved, Vet Approved
KetanserinKetanserin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetrahydropalmatine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tetrahydropalmatine.Approved, Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
LabetalolLabetalol may increase the hypotensive activities of Tetrahydropalmatine.Approved
LacidipineLacidipine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetrahydropalmatine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tetrahydropalmatine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tetrahydropalmatine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tetrahydropalmatine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Tetrahydropalmatine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetrahydropalmatine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetrahydropalmatine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tetrahydropalmatine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Tetrahydropalmatine.Approved, Investigational
LinsidomineTetrahydropalmatine may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetamineTetrahydropalmatine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Tetrahydropalmatine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Tetrahydropalmatine.Illicit
LofexidineLofexidine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tetrahydropalmatine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tetrahydropalmatine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Tetrahydropalmatine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Lormetazepam.Approved
LosartanLosartan may increase the hypotensive activities of Tetrahydropalmatine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tetrahydropalmatine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tetrahydropalmatine.Approved, Investigational
MacitentanTetrahydropalmatine may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Tetrahydropalmatine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Tetrahydropalmatine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Tetrahydropalmatine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe therapeutic efficacy of Tetrahydropalmatine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineManidipine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tetrahydropalmatine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Mebicar.Experimental
MecamylamineMecamylamine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Tetrahydropalmatine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Tetrahydropalmatine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tetrahydropalmatine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Tetrahydropalmatine.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Tetrahydropalmatine.Experimental
MephedroneTetrahydropalmatine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineTetrahydropalmatine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetrahydropalmatine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrahydropalmatine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Meptazinol.Experimental
MequitazineTetrahydropalmatine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tetrahydropalmatine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tetrahydropalmatine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Tetrahydropalmatine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tetrahydropalmatine.Approved, Illicit
MethamphetamineTetrahydropalmatine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tetrahydropalmatine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tetrahydropalmatine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tetrahydropalmatine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tetrahydropalmatine.Approved
MethoserpidineTetrahydropalmatine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
MethoxyphenamineTetrahydropalmatine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tetrahydropalmatine.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Tetrahydropalmatine.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tetrahydropalmatine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tetrahydropalmatine.Approved
MetipranololMetipranolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Tetrahydropalmatine.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Tetrahydropalmatine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
MetyrosineTetrahydropalmatine may increase the sedative activities of Metyrosine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Tetrahydropalmatine.Experimental
MibefradilMibefradil may increase the hypotensive activities of Tetrahydropalmatine.Investigational, Withdrawn
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetrahydropalmatine.Approved, Illicit
MidomafetamineTetrahydropalmatine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Milnacipran.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Tetrahydropalmatine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved, Investigational
MinoxidilMinoxidil may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Tetrahydropalmatine.Investigational
MirtazapineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDATetrahydropalmatine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Tetrahydropalmatine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Tetrahydropalmatine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Tetrahydropalmatine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetrahydropalmatine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
MuzolimineTetrahydropalmatine may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Tetrahydropalmatine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
NafcillinThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Tetrahydropalmatine.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Tetrahydropalmatine.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetrahydropalmatine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Tetrahydropalmatine.Approved, Investigational
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Tetrahydropalmatine.Approved
NebivololNebivolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Tetrahydropalmatine.Experimental
NiguldipineNiguldipine may increase the hypotensive activities of Tetrahydropalmatine.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Tetrahydropalmatine.Investigational
NilvadipineNilvadipine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Tetrahydropalmatine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetrahydropalmatine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
NitroprussideTetrahydropalmatine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tetrahydropalmatine.Approved, Vet Approved
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Tetrahydropalmatine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Tetrahydropalmatine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tetrahydropalmatine.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Tetrahydropalmatine.Approved, Vet Approved
ObinutuzumabTetrahydropalmatine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tetrahydropalmatine.Approved, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tetrahydropalmatine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Tetrahydropalmatine.Investigational
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Tetrahydropalmatine.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tetrahydropalmatine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Tetrahydropalmatine.Approved, Illicit
OrphenadrineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Tetrahydropalmatine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetrahydropalmatine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Oxethazaine.Approved, Investigational
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Tetrahydropalmatine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetrahydropalmatine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tetrahydropalmatine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrahydropalmatine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Tetrahydropalmatine.Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tetrahydropalmatine.Approved
ParaldehydeTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylinePargyline may increase the hypotensive activities of Tetrahydropalmatine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Paroxetine.Approved, Investigational
PenbutololPenbutolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Penfluridol.Experimental
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrahydropalmatine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Tetrahydropalmatine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved
PerazineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Perazine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Tetrahydropalmatine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Tetrahydropalmatine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tetrahydropalmatine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tetrahydropalmatine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Tetrahydropalmatine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Phenibut.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tetrahydropalmatine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Tetrahydropalmatine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Tetrahydropalmatine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
PhentermineTetrahydropalmatine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolaminePhentolamine may increase the hypotensive activities of Tetrahydropalmatine.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tetrahydropalmatine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tetrahydropalmatine.Approved
PinacidilPinacidil may increase the hypotensive activities of Tetrahydropalmatine.Approved
PindololPindolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tetrahydropalmatine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Tetrahydropalmatine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Piritramide.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Tetrahydropalmatine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Tetrahydropalmatine.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Tetrahydropalmatine.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tetrahydropalmatine.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational, Vet Approved
PramipexoleTetrahydropalmatine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tetrahydropalmatine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetrahydropalmatine.Approved, Illicit
PrazosinPrazosin may increase the hypotensive activities of Tetrahydropalmatine.Approved
PregabalinThe therapeutic efficacy of Tetrahydropalmatine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tetrahydropalmatine.Approved
PrimidoneThe metabolism of Tetrahydropalmatine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetrahydropalmatine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tetrahydropalmatine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Tetrahydropalmatine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tetrahydropalmatine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Tetrahydropalmatine.Approved
PropranololPropranolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tetrahydropalmatine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Tetrahydropalmatine.Investigational
PseudoephedrineTetrahydropalmatine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Tetrahydropalmatine.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tetrahydropalmatine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetrahydropalmatine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Tetrahydropalmatine.Approved, Investigational
QuinaprilQuinapril may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Tetrahydropalmatine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Raclopride.Investigational
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Tetrahydropalmatine.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tetrahydropalmatine.Approved, Investigational
RamiprilRamipril may increase the hypotensive activities of Tetrahydropalmatine.Approved
RasagilineRasagiline may increase the hypotensive activities of Tetrahydropalmatine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetrahydropalmatine.Approved
RemikirenRemikiren may increase the hypotensive activities of Tetrahydropalmatine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tetrahydropalmatine.Approved, Withdrawn
RescinnamineTetrahydropalmatine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetrahydropalmatine.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Tetrahydropalmatine.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Tetrahydropalmatine.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Tetrahydropalmatine.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Tetrahydropalmatine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
RiociguatTetrahydropalmatine may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Tetrahydropalmatine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ritanserin.Investigational
RitobegronTetrahydropalmatine may decrease the stimulatory activities of Ritobegron.Investigational
RituximabTetrahydropalmatine may increase the hypotensive activities of Rituximab.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Tetrahydropalmatine.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Tetrahydropalmatine.Vet Approved
RopiniroleTetrahydropalmatine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetrahydropalmatine.Approved
RotigotineTetrahydropalmatine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tetrahydropalmatine.Approved
SafrazineSafrazine may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Tetrahydropalmatine.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational, Vet Approved
SaprisartanSaprisartan may increase the hypotensive activities of Tetrahydropalmatine.Experimental
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrahydropalmatine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetrahydropalmatine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Tetrahydropalmatine.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Sepranolone.Investigational
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Tetrahydropalmatine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetrahydropalmatine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Tetrahydropalmatine.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Tetrahydropalmatine.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Tetrahydropalmatine.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
SitaxentanTetrahydropalmatine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved
SpiraprilSpirapril may increase the hypotensive activities of Tetrahydropalmatine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Tetrahydropalmatine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrahydropalmatine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Tetrahydropalmatine.Approved
SulpirideTetrahydropalmatine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Tetrahydropalmatine.Approved, Investigational
SuvorexantTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Tetrahydropalmatine.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Tetrahydropalmatine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Tetrahydropalmatine.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Tetrahydropalmatine.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tetrahydropalmatine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Tetrahydropalmatine.Experimental, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Tetrahydropalmatine.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Tetrahydropalmatine.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tetrahydropalmatine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tetrahydropalmatine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tetrahydropalmatine.Investigational
ThalidomideTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineTetrahydropalmatine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetrahydropalmatine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetrahydropalmatine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tetrahydropalmatine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tetrahydropalmatine.Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Tetrahydropalmatine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Tetrahydropalmatine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Tiapride.Approved, Investigational
TiboloneTibolone may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Tetrahydropalmatine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Tilidine.Experimental
TimololTimolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Tetrahydropalmatine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tetrahydropalmatine.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Tetrahydropalmatine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tetrahydropalmatine.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Tetrahydropalmatine.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational, Vet Approved
TolonidineTetrahydropalmatine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Tetrahydropalmatine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tetrahydropalmatine.Approved
TorasemideTorasemide may increase the hypotensive activities of Tetrahydropalmatine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetrahydropalmatine.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Tetrahydropalmatine.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetrahydropalmatine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Tetrahydropalmatine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Tetrahydropalmatine.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tetrahydropalmatine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Tetrahydropalmatine.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetrahydropalmatine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tetrahydropalmatine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Tetrahydropalmatine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tetrahydropalmatine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tetrahydropalmatine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Tetrahydropalmatine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Tetrahydropalmatine.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tetrahydropalmatine.Approved, Investigational
ValsartanValsartan may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Tetrahydropalmatine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tetrahydropalmatine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Tetrahydropalmatine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Tetrahydropalmatine.Approved
VincamineTetrahydropalmatine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineTetrahydropalmatine may increase the hypotensive activities of Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Vinyl ether.Experimental
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Tetrahydropalmatine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tetrahydropalmatine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Xenon.Experimental
XipamideTetrahydropalmatine may increase the hypotensive activities of Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Tetrahydropalmatine.Vet Approved
XylometazolineXylometazoline may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Tetrahydropalmatine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tetrahydropalmatine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Tetrahydropalmatine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetrahydropalmatine.Approved
ZofenoprilTetrahydropalmatine may increase the hypotensive activities of Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Tetrahydropalmatine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tetrahydropalmatine.Approved, Investigational
ZolpidemTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tetrahydropalmatine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tetrahydropalmatine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Tetrahydropalmatine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetrahydropalmatine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C02890
PubChem Compound
72301
PubChem Substance
347828397
ChemSpider
65252
BindingDB
50424077
ChEBI
16563
ChEMBL
CHEMBL487182
Wikipedia
Tetrahydropalmatine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0246 mg/mLALOGPS
logP3.09ALOGPS
logP3.15ChemAxon
logS-4.2ALOGPS
pKa (Strongest Basic)5.34ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.16 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity101.36 m3·mol-1ChemAxon
Polarizability39.97 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as protoberberine alkaloids and derivatives. These are alkaloids with a structure based on a protoberberine moiety, which consists of a 5,6-dihydrodibenzene moiety fused to a quinolizinium and forming 5,6-Dihydrodibenzo(a,g)quinolizinium skeleton.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Protoberberine alkaloids and derivatives
Sub Class
Not Available
Direct Parent
Protoberberine alkaloids and derivatives
Alternative Parents
Tetrahydroisoquinolines / Anisoles / Aralkylamines / Alkyl aryl ethers / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Protoberberine skeleton / Tetrahydroprotoberberine skeleton / Tetrahydroisoquinoline / Anisole / Alkyl aryl ether / Aralkylamine / Benzenoid / Tertiary amine / Tertiary aliphatic amine / Ether
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heterotetracyclic compound, berberine alkaloid (CHEBI:16563) / Isoquinoline alkaloids (C02890)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Mantsch JR, Li SJ, Risinger R, Awad S, Katz E, Baker DA, Yang Z: Levo-tetrahydropalmatine attenuates cocaine self-administration and cocaine-induced reinstatement in rats. Psychopharmacology (Berl). 2007 Jul;192(4):581-91. Epub 2007 Mar 15. [PubMed:17361394]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Mantsch JR, Li SJ, Risinger R, Awad S, Katz E, Baker DA, Yang Z: Levo-tetrahydropalmatine attenuates cocaine self-administration and cocaine-induced reinstatement in rats. Psychopharmacology (Berl). 2007 Jul;192(4):581-91. Epub 2007 Mar 15. [PubMed:17361394]

Drug created on October 20, 2016 15:20 / Updated on March 02, 2018 05:30